SymBio Pharma completes patient enrollment in phase II trial of Treakisym in ... pharmabiz.com Currently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of rituximab and bendamustine (R-B) over R-CHOP in terms of safety and efficacy, leading to the ... |
